Combogesic

Combogesic: Each tablet contains Ibuprofen (Combogesic) 300 mg and Paracetamol (Combogesic) 325 mg.

Combogesic Kid: Each dispersible tablet contains Ibuprofen (Combogesic) 100 mg and Paracetamol (Combogesic) 125 mg. Colour: Tartrazine.

Combogesic Forte: Each tablet contains Ibuprofen (Combogesic) 400 mg and Paracetamol (Combogesic) 500 mg.

Combogesic Ophthalmic Solution is indicated for inhibition of intraoperative miosis.

For oral use for adult single dose is 25-50 mg 2-3 times / 24 h. Frequency of admission depends on the dosage form employed, the severity of the disease and is 1-3 times / 24 h, rectally - 1 times / 24 h, for the treatment of acute conditions or the exacerbation of chronic edema use intramuscular in dose of 75 mg.

For children older than 6 years and adolescents daily dose is 2 mg / kg.

Topical applied at a dose of 2-4 g (depending on the size of painful area) on the affected area 3-4 times / 24 h.

When used in ophthalmology frequency and duration of administration are determined individually.

The maximum oral daily dose for adults is 150 mg.

Combogesic is contraindicated in patients with the following conditions: History of severe allergic reaction eg, anaphylaxis or angioedema induced by aspirin or other NSAIDs. Because of the possibility of cross-sensitivity due to structural relationships which exist among non-steroidal anti-inflammatory medicines, acute allergic reactions are likely to occur in patients who have exhibited allergic reactions to these compounds.

Patients sensitive to any of the ingredients.

Aspirin-induced nasal polyps associated with bronchospasm (high risk of severe allergic reactions because of cross-sensitivity).

Active peptic ulceration.

Severe renal function impairment.

Clinical studies with acetylcholine chloride revealed no interference, and there is no known pharmacological basis for such an interaction. However, with other topical nonsteroidal anti-inflammatory products, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with these agents.

Interaction of Combogesic with other topical ophthalmic medications has not been fully investigated.

Ocular

The most frequent adverse reactions reported are burning and stinging of short duration. Instances of discomfort, itching and redness have been reported. Other reactions occurring in less than 0.5% of patients include allergy, iritis, pain, chemosis, photophobia, irritation, and punctate epithelial staining.

Systemic

Systemic reactions related to therapy were not reported in the clinical studies. It is known that some systemic absorption does occur with ocularly applied drugs, and that nonsteroidal anti-inflammatory drugs have been shown to increase bleeding time by interference with thrombocyte aggregation. It is recommended that Combogesic be used with caution in patients with bleeding tendencies and those taking anticoagulants.